Literature DB >> 33505922

Burkitt Lymphomas Evolve to Escape Dependencies on Epstein-Barr Virus.

Rebecca L Hutcheson1, Adityarup Chakravorty1, Bill Sugden1.   

Abstract

Epstein-Barr Virus (EBV) can transform B cells and contributes to the development of Burkitt lymphoma and other cancers. Through decades of study, we now recognize that many of the viral genes required to transform cells are not expressed in EBV-positive Burkitt lymphoma (BL) tumors, likely due to the immune pressure exerted on infected cells. This recognition has led to the hypothesis that the loss of expression of these viral genes must be compensated through some mechanisms. Recent progress in genome-wide mutational analysis of tumors provides a wealth of data about the cellular mutations found in EBV-positive BLs. Here, we review common cellular mutations found in these tumors and consider how they may compensate for the viral genes that are no longer expressed. Understanding these mutations and how they may substitute for EBV's genes and contribute to lymphomagenesis can serve as a launchpad for more mechanistic studies, which will help us navigate the sea of genomic data available today, and direct the discoveries necessary to improve the treatment of EBV-positive BLs.
Copyright © 2021 Hutcheson, Chakravorty and Sugden.

Entities:  

Keywords:  B cell; Burkitt lymphoma; Epstein–Barr virus; cellular mutations; compensation; next-generation sequencing; tumor evolution

Year:  2021        PMID: 33505922      PMCID: PMC7829347          DOI: 10.3389/fcimb.2020.606412

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   5.293


  120 in total

1.  The structure of the termini of the DNA of Epstein-Barr virus.

Authors:  C R Kintner; B Sugden
Journal:  Cell       Date:  1979-07       Impact factor: 41.582

2.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

3.  Epstein-Barr virus oncoprotein super-enhancers control B cell growth.

Authors:  Hufeng Zhou; Stefanie C S Schmidt; Sizun Jiang; Bradford Willox; Katharina Bernhardt; Jun Liang; Eric C Johannsen; Peter Kharchenko; Benjamin E Gewurz; Elliott Kieff; Bo Zhao
Journal:  Cell Host Microbe       Date:  2015-01-29       Impact factor: 21.023

4.  EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.

Authors:  L-M Cai; X-M Lyu; W-R Luo; X-F Cui; Y-F Ye; C-C Yuan; Q-X Peng; D-H Wu; T-F Liu; E Wang; F-M Marincola; K-T Yao; W-Y Fang; H-B Cai; X Li
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

5.  Global burden of cancers attributable to infections in 2012: a synthetic analysis.

Authors:  Martyn Plummer; Catherine de Martel; Jerome Vignat; Jacques Ferlay; Freddie Bray; Silvia Franceschi
Journal:  Lancet Glob Health       Date:  2016-07-25       Impact factor: 26.763

6.  Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.

Authors:  N Kitagawa; M Goto; K Kurozumi; S Maruo; M Fukayama; T Naoe; M Yasukawa; K Hino; T Suzuki; S Todo; K Takada
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

7.  Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis.

Authors:  Ulrike Dirmeier; Reinhard Hoffmann; Ellen Kilger; Ute Schultheiss; Cinthia Briseño; Olivier Gires; Arnd Kieser; Dirk Eick; Bill Sugden; Wolfgang Hammerschmidt
Journal:  Oncogene       Date:  2005-03-03       Impact factor: 9.867

8.  Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.

Authors:  Sizun Jiang; Bradford Willox; Hufeng Zhou; Amy M Holthaus; Anqi Wang; Tommy T Shi; Seiji Maruo; Peter V Kharchenko; Eric C Johannsen; Elliott Kieff; Bo Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

9.  The viral and cellular microRNA targetome in lymphoblastoid cell lines.

Authors:  Rebecca L Skalsky; David L Corcoran; Eva Gottwein; Christopher L Frank; Dong Kang; Markus Hafner; Jeffrey D Nusbaum; Regina Feederle; Henri-Jacques Delecluse; Micah A Luftig; Thomas Tuschl; Uwe Ohler; Bryan R Cullen
Journal:  PLoS Pathog       Date:  2012-01-26       Impact factor: 6.823

10.  Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells.

Authors:  Jens S Kalchschmidt; Rachael Bashford-Rogers; Kostas Paschos; Adam C T Gillman; Christine T Styles; Paul Kellam; Martin J Allday
Journal:  J Exp Med       Date:  2016-05-23       Impact factor: 14.307

View more
  3 in total

Review 1.  Virus-Mediated Inhibition of Apoptosis in the Context of EBV-Associated Diseases: Molecular Mechanisms and Therapeutic Perspectives.

Authors:  Zbigniew Wyżewski; Matylda Barbara Mielcarska; Karolina Paulina Gregorczyk-Zboroch; Anna Myszka
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

2.  Epigenetic Alteration of the Cancer-Related Gene TGFBI in B Cells Infected with Epstein-Barr Virus and Exposed to Aflatoxin B1: Potential Role in Burkitt Lymphoma Development.

Authors:  Francesca Manara; Antonin Jay; Grace Akinyi Odongo; Fabrice Mure; Mohamed Ali Maroui; Audrey Diederichs; Cecilia Sirand; Cyrille Cuenin; Massimo Granai; Lucia Mundo; Hector Hernandez-Vargas; Stefano Lazzi; Rita Khoueiry; Henri Gruffat; Zdenko Herceg; Rosita Accardi
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

Review 3.  EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis.

Authors:  Tingting Yang; Chanping You; Shuhui Meng; Zhengquan Lai; Weipeng Ai; Jun Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.